{
    "clinical_study": {
        "@rank": "89297", 
        "acronym": "SIESTA", 
        "arm_group": [
            {
                "arm_group_label": "Trazodone", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is a randomized, double-blind clinical trial comparing trazodone (Desyrel) and\n      placebo among sleep-disturbed, alcohol-dependent individuals shortly after discharge from an\n      inpatient detoxification program. Subjects will undergo a baseline assessment and random\n      assignment to trazodone or identical placebo for 12 weeks.  All persons completing the\n      alcohol detoxification at Stanley Street Treatment and Resources (SSTAR) will be screened.\n      (SSTAR of Rhode Island provides detoxification services to non/underinsured persons of Rhode\n      Island.)"
        }, 
        "brief_title": "Trazodone for Sleep Disturbance in Early Alcohol Recovery", 
        "completion_date": {
            "#text": "June 2006", 
            "@type": "Actual"
        }, 
        "condition": "Alcoholism", 
        "condition_browse": {
            "mesh_term": [
                "Alcoholism", 
                "Sleep Disorders", 
                "Dyssomnias", 
                "Parasomnias"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Completed an alcohol detoxification program.\n\n          -  Meets criteria for alcohol dependence.\n\n          -  Meets criteria for sleep disturbance.\n\n          -  If female of childbearing potential must be using adequate contraception.\n\n          -  Has a location to which they will return after the initial research interview and a\n             person they regularly contact.\n\n          -  Speaks English sufficiently to understand instructions and assessment.\n\n        Exclusion Criteria:\n\n          -  Meets criteria for substance dependence for sedative/hypnotic drugs, stimulants,\n             cocaine or opiates, or of organic brain disorder, bipolar disorder, schizophrenia,\n             schizoaffective, schizophreniform, or paranoid disorder, or major depression.\n\n          -  Current suicidality.\n\n          -  Use of psychotropic, antidepressant, anxiolytic or antidipsogenic medication.\n\n          -  Inability or refusal to terminate the use of proerectile agents, herbal medications\n             or sleep medication for the study period.\n\n          -  The presence of contraindications to the  study medications, including\n             pregnancy/lactation, ischemic heart disease, cardiac arrhythmias, priapism or\n             hypotension.\n\n          -  Presence of comorbid medical conditions associated with sleep disturbance including\n             obstructive sleep apnea, poorly controlled diabetes mellitus or emphysema.\n\n          -  Evidence of neuropsychological dysfunction.\n\n          -  Probation/parole requirements that might interfere with participation in study.\n\n          -  Inability to identify at least one contact person.\n\n          -  Living on the street after detoxification (homeless persons living in a shelter,\n             halfway house or other residence will not be excluded)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "173", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 19, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00027053", 
            "org_study_id": "NIAAAFRI13243", 
            "secondary_id": [
                "R01AA013243", 
                "NIH grant R01 AA013243"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Trazodone", 
                "description": "50 to 150 mg qhs", 
                "intervention_name": "Trazodone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Trazodone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "alcoholism", 
            "alcohol dependence", 
            "trazadone", 
            "sleep"
        ], 
        "lastchanged_date": "May 11, 2010", 
        "location": {
            "facility": {
                "address": {
                    "city": "Providence", 
                    "country": "United States", 
                    "state": "Rhode Island", 
                    "zip": "02903"
                }, 
                "name": "Rhode Island Hospital"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Trazodone for Sleep Disturbance - Early Alcohol Recovery", 
        "overall_official": {
            "affiliation": "Rhode Island Hospital", 
            "last_name": "Peter D. Friedmann, MD, MPH", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2006", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Percent days abstinent from alcohol (PDA)", 
            "safety_issue": "No", 
            "time_frame": "12 and 24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00027053"
        }, 
        "responsible_party": {
            "name_title": "Peter Friedmann", 
            "organization": "Rhode Island Hospital"
        }, 
        "results_reference": {
            "PMID": "18616688", 
            "citation": "Friedmann PD, Rose JS, Swift R, Stout RL, Millman RP, Stein MD. Trazodone for sleep disturbance after alcohol detoxification: a double-blind, placebo-controlled trial. Alcohol Clin Exp Res. 2008 Sep;32(9):1652-60. Epub 2008 Jul 8."
        }, 
        "secondary_outcome": [
            {
                "measure": "sleep quality", 
                "safety_issue": "No", 
                "time_frame": "12 and 24 weeks"
            }, 
            {
                "measure": "Drinks per drinking day", 
                "safety_issue": "No", 
                "time_frame": "12 and 24 weeks"
            }
        ], 
        "source": "Rhode Island Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Rhode Island Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2002", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2006"
    }, 
    "geocoordinates": {
        "Rhode Island Hospital": "41.824 -71.413"
    }
}